Adagene (ADAG) Stock Price, News & Analysis

Company Overview

Adagene Inc., headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability. The immunome platform enables rapid identification of high-quality antibody candidates derived from healthy donor B cells, while the AI-driven design engine accelerates selection and engineering, aiming to streamline candidate advancement toward investigational new drug filings and clinical trials.

Adagene operates research facilities in Suzhou and maintains an office in Cambridge, Massachusetts, serving global markets through strategic collaborations with leading pharmaceutical partners. The company’s leadership team is led by founder and CEO Dr. Ying Yan, whose expertise in antibody discovery and immuno-oncology has driven the development of its platform-based strategy. Under her guidance, Adagene has expanded its research capabilities and advanced multiple therapeutic candidates into the clinic.

Key Stats

• Today's Range: $4.41 to $4.78
• 50-Day Range: $3.26 to $4.78
• 52-Week Range: $1.30 to $4.85
• Volume: 81,655 shs
• Average Volume: 283,281 shs
• Market Capitalization: $211.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Adagene Stock Analysis - MarketRank™

Adagene scored higher than 36% of companies evaluated by MarketBeat, and ranked 627th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Adagene has a consensus price target of $8.00, representing about 79.0% upside from its current price of $4.47.

Amount of Analyst Coverage

Adagene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adagene are expected to grow in the coming year, from ($0.49) to ($0.48) per share.

Price to Book Value per Share Ratio

Adagene has a P/B Ratio of 5.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.96% of the float of Adagene has been sold short.

Short Interest Ratio / Days to Cover

Adagene has a short interest ratio ("days to cover") of 12.11, which indicates bearish sentiment.

Change versus previous month

Short interest in Adagene has recently increased by 45.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adagene does not currently pay a dividend.

Dividend Growth

Adagene does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Adagene this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adagene insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.51% of the stock of Adagene is held by institutions.

Company Calendar

• Last Earnings: 2/14/2026
• Today: 7/03/2026
• Next Earnings (Estimated): 9/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADAG
• CIK: 1818838
• Web: www.adagene.com
• Phone: 86-512-8777-3632
• Fax: N/A
• Employees: 260
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Adagene: $8.00
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +79.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 3.07
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: $7.67 million
• Price / Sales: 27.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.75 per share
• Price / Book: 5.96

Miscellaneous

• Outstanding Shares: 47,390,000
• Free Float: 37,340,000
• Market Cap: $211.83 million
• Optionable: Not Optionable
• Beta: 0.58